Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > nosh
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Jun 04, 2021 2:39pm
115 Views
Post# 33331149

RE:RE:nosh

RE:RE:nosh
Actuarial wrote:
If you have reviewed Avicenna pipeline, you would understand why NOSH is not a competition to ATE yet. And if you Google the details of NOSH patent, you will see a name Wallace in the reference. Ha, NOSH might be a competition someday. However, the someday is far far away as Avicenna has nothing serious yet . And their patents rely on ATE platform. Even they might have something better, they have to wait for h2s patents expiring and exclusive right expires. We have enough time to harvest investment.
Nick80 wrote: Hi what are you guys think about:
https://www.avicennatherapeutics.com/technology

Would they be serious competition for ate 346, 352 or 340?

From my understanding their platform might outperform ATE's 340 drug if successful, however what about 346 and others? 

Their nosh platform is in pre-clinical only meaning ate is very well advanced and derisked compared to them... 




Thanks Actuarial ... interesting points.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities